Source: Virtual Congress 2020 – Air pollution and comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Trudzinski (Heidelberg, Germany), C. Vogelmeier (Marburg, Germany), R. Buhl (Mainz, Germany), F. Trinkmann (Heidelberg, Germany), V. Obermoser (Nürnberg, Germany), P. Kardos (Frankfurt, Germany), C. Criée (Bovenden, Germany), H. Worth (Fürth, Germany). Inhaled steroids and prevalence of osteoporosis in chronic obstructive pulmonary disease: Data from the DACCORD cohort. 127

Member's Comments

No comment yet.

Related content which might interest you: Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 202-203 Year: 2003 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Doxycycline for exacerbations of chronic obstructive pulmonary disease in outpatients: who benefits? Source: ERJ Open Res, 6 (2) 00099-2020; 10.1183/23120541.00099-2020 Year: 2020 Correlates of osteoporosis in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Inhaled budesonide in the management of chronic obstructive pulmonary diseases Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Prescription of opioids for breathlessness in end-stage chronic obstructive pulmonary disease: A national population based study Source: International Congress 2016 – Management of dyspnoea and exacerbations in chronic lung diseases Year: 2016 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003 Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 427s Year: 2003 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Management of chronic obstructive pulmonary disease (COPD) exacerbations: results of a French cohort study Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 A preliminary meta-analysis of long-term inhaled steroids for stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Acute exacerbations of chronic obstructive pulmonary disease: Impact of cardiovascular co-morbidities Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD Year: 2010 Comorbidities in chronic obstructive pulmonary disease: a nation-wide twin study Source: International Congress 2018 – New determinants of cardiovascular morbidity in COPD Year: 2018 Risk of pneumonia in chronic obstructive pulmonary disease patients treated with inhaled corticosteroids. Results from the OUTPUL study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 The association of diuretics treatment with hospitalization rates of patients with chronic obstructive pulmonary disease and pulmonary hypertension: a population-based study Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 521s Year: 2004 Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Effect of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 624s Year: 2006